Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
QuintilesIMS
Dow
Harvard Business School
Daiichi Sankyo
Queensland Health
Johnson and Johnson
US Department of Justice
Chubb

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RETAPAMULIN

« Back to Dashboard

Clinical Trials for Retapamulin

Trial ID Title Status Sponsor Phase Summary
NCT00539994 Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus Completed GlaxoSmithKline Phase 2 This is a Phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and efficacy of Retapamulin ointment, 1% applied twice daily for 3 or 5 days to the anterior nares of healthy adult subjects who are nasally colonized with S. aureus. Approximately 57 healthy subjects who are nasal carriers of S. aureus will be enrolled and stratified in a 2:1 ratio so that at least 38 persistent carriers and 19 intermittent carriers complete the study. Each eligible subject will participate in three screening visits, a treatment period, and two follow-up visits. Each subject's participation in the study will be approximately 6 to 10 weeks from screening to the last follow-up visit. Subjects will participate in up to three screening visits to determine S. aureus culture positivity and colonization status.
NCT00555061 Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections. Completed GlaxoSmithKline Phase 4 A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).
NCT00684177 Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL) Completed GlaxoSmithKline Phase 3 The purpose of Study TOC110977 is to demonstrate clinical superiority of Retapamulin ointment, 1%, over placebo in patients with secondarily-infected traumatic lesions, which includes secondarily-infected lacerations, abrasions and sutured wounds. Subjects 2 months of age and older will be treated with topical retapamulin or placebo ointment twice daily for 5 days. The primary endpoint of this study is the clinical response at follow-up (Day 12-14; 7-9 days after the end of therapy) in the intent-to-treat clinical population.
NCT00852540 Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA Completed GlaxoSmithKline Phase 3 The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA. Subjects aged 2 months and older will be treated with either topical retapamulin for 5 days or oral linezolid for 10 days. The primary endpoint is the clinical response at follow-up (7-9 days after the end of therapy) in subjects who have a MRSA infection at baseline. The primary population is the per-protocol MRSA population. It is anticipated that approximately 500 subjects may be enrolled in order to obtain approximately 105 subjects who have a baseline MRSA infection.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Retapamulin

Condition Name

Condition Name for Retapamulin
Intervention Trials
Skin Infections, Bacterial 6
Methicillin-Resistant Staphylococcus Aureus 3
Impetigo 3
MRSA 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Retapamulin
Intervention Trials
Bacterial Infections 7
Skin Diseases, Infectious 6
Staphylococcal Infections 4
Impetigo 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Retapamulin

Trials by Country

Trials by Country for Retapamulin
Location Trials
United States 59
Argentina 3
South Africa 3
Germany 2
Brazil 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Retapamulin
Location Trials
California 5
Florida 4
Texas 4
New York 4
Louisiana 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Retapamulin

Clinical Trial Phase

Clinical Trial Phase for Retapamulin
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Retapamulin
Clinical Trial Phase Trials
Completed 12
Withdrawn 2
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Retapamulin

Sponsor Name

Sponsor Name for Retapamulin
Sponsor Trials
GlaxoSmithKline 11
Gary Goldenberg 1
Ochsner Health System 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Retapamulin
Sponsor Trials
Industry 13
Other 7
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
QuintilesIMS
Deloitte
US Army
Harvard Business School
Teva
Fuji
Fish and Richardson
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.